Management of Preeclampsia

Initial Assessment and Risk Stratification

• The American College of Obstetricians and Gynecologists recommends that preeclampsia is defined as new-onset hypertension (≥140/90 mmHg) after 20 weeks' gestation, and while proteinuria was historically required, it is no longer mandatory for diagnosis 1
• Proteinuria is confirmed by ≥300 mg/24 hours, spot urine protein/creatinine ratio ≥30 mg/mmol (or 0.3 mg/mg), or ≥1+ on dipstick testing 1, 2
• All cases of preeclampsia should be treated as potentially severe, as rapid progression to life-threatening complications can occur even with initially mild presentations 2, 3

Severity Assessment

• Severe features include severe hypertension: BP ≥160/110 mmHg on two occasions at least 15 minutes apart 2
• Severe features include thrombocytopenia: platelets <100,000/μL 2
• Severe features include renal dysfunction: creatinine >1.1 mg/dL or doubling of baseline 2
• Severe features include visual disturbances (scotomata, cortical blindness) 2

Immediate Stabilization for Severe Preeclampsia

• Urgent antihypertensive therapy must be initiated immediately when BP ≥160/110 mmHg persists for >15 minutes to prevent maternal cerebral hemorrhage 2, 3
• First-line IV antihypertensive options include IV labetalol: 20 mg IV bolus, then 40 mg after 10 minutes, then 80 mg every 10 minutes (maximum cumulative dose 220 mg) 3
• First-line IV antihypertensive options include IV hydralazine: 5-10 mg IV every 20 minutes as needed 3
• Target blood pressure: Systolic 110-140 mmHg and diastolic 85 mmHg (or at minimum <160/105 mmHg) 2, 3

Seizure Prophylaxis with Magnesium Sulfate

• Magnesium sulfate must be administered immediately to all patients with severe preeclampsia or those with proteinuria plus severe hypertension or any neurological symptoms 2, 3
• Loading dose: 4-5 g IV over 5 minutes (diluted in 250 mL of 5% dextrose or 0.9% normal saline) 3
• Maintenance: 1-2 g/hour continuous IV infusion 3

Comprehensive Laboratory and Fetal Assessment

• Initial laboratory workup should include complete blood count with focus on hemoglobin and platelet count 2
• Initial laboratory workup should include comprehensive metabolic panel: liver transaminases (AST/ALT), creatinine, uric acid 2
• Initial laboratory workup should include spot urine protein/creatinine ratio 2

Delivery Timing: Gestational Age-Based Algorithm

• Immediate delivery is indicated after maternal stabilization at ≥37 weeks' gestation 2, 4, 3
• Without severe features at 34-37 weeks' gestation, expectant management with close monitoring is appropriate 2, 3
• With severe features at 34-37 weeks' gestation, deliver after maternal stabilization 3

Absolute Indications for Immediate Delivery (Any Gestational Age)

• Deliver immediately regardless of gestational age if inability to control BP despite ≥3 classes of antihypertensives in appropriate doses 2
• Deliver immediately regardless of gestational age if placental abruption 1
• Deliver immediately regardless of gestational age if non-reassuring fetal status on continuous monitoring 4
• Deliver immediately regardless of gestational age if maternal oxygen saturation deterioration (<90%) 2

Special Considerations and Critical Pitfalls

• HELLP syndrome is defined by hemolysis, elevated liver enzymes, and low platelets 3
• Maternal mortality rate is 3.4% in HELLP syndrome 3
• Epigastric or right upper quadrant pain is a hallmark symptom of HELLP syndrome 3
• Monitor glucose intraoperatively as severe hypoglycemia can occur in HELLP syndrome 3
• Drug of choice for pulmonary edema is IV nitroglycerin (glycerol trinitrate) starting at 5 mcg/min, gradually increased every 3-5 minutes to maximum 100 mcg/min 3
• Plasma volume expansion is NOT recommended routinely for pulmonary edema 2, 3
• Do not underestimate disease severity based on "mild" classification—all preeclampsia can rapidly progress 2, 4, 3
• Blood pressure alone is not a reliable indicator of disease severity—serious organ dysfunction can develop at relatively mild levels of hypertension 2
• Do not use serum uric acid or level of proteinuria as indication for delivery 2, 3
• Do not delay delivery at ≥37 weeks based on non-reactive NST—delivery is indicated regardless of fetal testing results 4
• Do not reduce antihypertensives if diastolic BP falls <80 mmHg 3
• Do not use diuretics routinely—they further reduce plasma volume which is already contracted in preeclampsia 3

Preeclampsia Management Guidelines

Introduction to Preeclampsia Management

• The International Society for the Study of Hypertension in Pregnancy recommends delivery in women with preeclampsia who develop progressively abnormal renal or liver enzyme tests, not simply elevated values 5
• Elevated liver enzymes (AST/ALT ≥2x upper limit of normal) define a severe feature of preeclampsia and signify more serious disease 6

Indications for Immediate Delivery

• Deliver immediately at any gestational age if there are repeated episodes of severe hypertension (≥160/110 mmHg) despite treatment with 3 classes of antihypertensives 5
• Deliver immediately at any gestational age if there is progressive thrombocytopenia (declining platelet counts on serial measurements) 5
• Deliver immediately at any gestational age if there are progressively abnormal liver or renal function tests (worsening trends, not static elevations) 5
• Deliver immediately at any gestational age if there is pulmonary edema 5
• Deliver immediately at any gestational age if there are abnormal neurological features: severe intractable headache, repeated visual scotomata, or eclamptic seizures 5
• Deliver immediately at any gestational age if there is non-reassuring fetal status 5

Monitoring and Management

• Obtain laboratory tests at least twice weekly including hemoglobin, platelet count, liver enzymes (AST/ALT), creatinine, and uric acid in women with elevated liver enzymes but not progressively worsening 5
• Initiate serial fetal surveillance with ultrasound for biometry, amniotic fluid volume, and umbilical artery Doppler in women with elevated liver enzymes but not progressively worsening 5
• Uric acid levels should not be used as an indication for delivery, but are included in monitoring protocols because they correlate with disease severity and complications like hepatic dysfunction and preterm delivery 5

HELLP Syndrome Management

• HELLP syndrome is considered part of the preeclampsia spectrum, not a separate disorder, and should be managed as having severe preeclampsia with all features sought and addressed 6, 7

Gestational Age-Specific Management

• At ≥37 weeks' gestation, deliver all women with preeclampsia regardless of laboratory values 5

Management of Preeclampsia

Initial Assessment and Diagnosis

• The American College of Cardiology recommends delivering all women with preeclampsia at ≥37 weeks' gestation regardless of severity, and immediately stabilizing severe hypertension with antihypertensive therapy plus magnesium sulfate for seizure prophylaxis when severe features are present 8
• Proteinuria is no longer mandatory for diagnosis, but when present is confirmed by spot urine protein/creatinine ratio ≥30 mg/mmol, ≥300 mg/24 hours, or ≥1+ on dipstick 9

Severity Classification: Identify Severe Features Immediately

• Severe features requiring urgent intervention include pulmonary edema 8

Immediate Stabilization for Severe Hypertension

• The American Heart Association recommends targeting systolic BP 110-140 mmHg and diastolic BP 85 mmHg (or at minimum <160/105 mmHg) 8

Delivery Timing: Gestational Age-Based Algorithm

• The American College of Obstetricians and Gynecologists recommends delivering immediately after maternal stabilization at ≥37 weeks' gestation 8
• At 34-37 weeks' gestation, deliver after maternal stabilization if severe features are present 8

Absolute Indications for Immediate Delivery (Any Gestational Age)

• The American College of Cardiology recommends delivering immediately regardless of gestational age if severe hypertension, progressive thrombocytopenia, or pulmonary edema develop 8

Postpartum Management

• The American Heart Association recommends monitoring BP and clinical condition at least every 4 hours while awake, and continuing antihypertensives administered antenatally 8, 9
• The American College of Cardiology recommends avoiding NSAIDs for postpartum analgesia unless other analgesics are not working, especially if renal disease or placental abruption are present 8, 9

Follow-Up and Long-Term Considerations

• The American College of Cardiology recommends reviewing all women at 3 months postpartum to ensure BP, urinalysis, and laboratory abnormalities have normalized, and initiating appropriate referral for further investigations if proteinuria or hypertension persists 8, 9
• Women with preeclampsia have significant long-term cardiovascular risks requiring annual medical review life-long 8, 9

Management of Preeclampsia

Initial Assessment and Risk Stratification

• The American College of Cardiology recommends that proteinuria is no longer mandatory for diagnosis of preeclampsia, though when present it is confirmed by spot urine protein/creatinine ratio ≥30 mg/mmol, ≥300 mg/24 hours, or ≥1+ on dipstick, in patients with new-onset hypertension ≥140/90 mmHg after 20 weeks' gestation 10

Immediate Stabilization for Severe Hypertension

• The American Heart Association suggests that for non-severe hypertension, acceptable oral agents include methyldopa, labetalol, oxprenolol, and nifedipine, with second or third-line agents including hydralazine and prazosin, in patients with preeclampsia 10
• The American College of Obstetricians and Gynecologists recommends that target blood pressure should be systolic 110-140 mmHg and diastolic 85 mmHg, in patients with severe hypertension 10

Seizure Prophylaxis with Magnesium Sulfate

• The American Academy of Neurology recommends that magnesium sulfate should be administered immediately to all patients with severe preeclampsia, proteinuria plus severe hypertension, or any hypertension with neurological symptoms, to prevent seizures 10

Comprehensive Laboratory and Monitoring Protocol

• The National Institute of Child Health and Human Development recommends that blood pressure should be monitored at least twice weekly or continuously if severe features are present, in patients with preeclampsia 10
• The American College of Cardiology suggests that laboratory tests, including hemoglobin, platelet count, liver enzymes, creatinine, and uric acid, should be repeated at least twice weekly, in patients with preeclampsia 10

Setting of Care

• The Society for Maternal-Fetal Medicine recommends that women with preeclampsia should be assessed in hospital when first diagnosed, and those with severe features should be managed in facilities with appropriate obstetrical care, maternal intensive care capabilities, and NICU for premature infants 10

High‑Risk Surveillance for Preeclampsia in Assisted Reproductive Pregnancies

1. Risk Assessment

• A first‑degree family history of severe preeclampsia roughly triples the risk of developing preeclampsia (relative risk ≈ 2.9)【11】.
• Two prior spontaneous abortions are associated with underlying placental dysfunction that raises the likelihood of hypertensive pregnancy complications【12】.

2. Guideline Definitions

• The International Society for the Study of Hypertension in Pregnancy (ISSHP) and the PRECOG consortium define explicit criteria for “high‑risk” surveillance, requiring intensified monitoring and specialist involvement【11】.
• According to these guidelines, any patient with ≥ 2 moderate risk factors must receive early specialist assessment (before 20 weeks gestation) and cannot be managed with an intermediate‑risk pathway【13】.
• Pregnancies resulting from oocyte donation are categorised as high risk and should be cared for in obstetric units equipped with maternal intensive‑care and neonatal intensive‑care facilities【14】.

3. Maternal Monitoring Protocol

• Blood pressure – Measure at least every 2 weeks until 32 weeks, then weekly until delivery; aim for a target of 110‑140/85 mm Hg【12】.
• Proteinuria – Perform urine protein‑to‑creatinine ratio at each visit; values ≥ 30 mg/mmol are considered pathological【15】.
• Laboratory tests – Every 2 weeks obtain a complete blood count (platelets), liver transaminases, serum creatinine and uric acid【15】.
• Clinical review – At each visit actively inquire about headache, visual changes, epigastric pain and assess for clonus【16】.

4. Fetal Surveillance

• Uterine‑artery Doppler – Baseline scan at diagnosis; repeat every 2 weeks if normal, with more frequent studies if fetal growth restriction is suspected【16】.
• Fetal biometry & amniotic fluid – Ultrasound every 2 weeks to detect early growth restriction【16】.

5. Management of Severe Hypertension

• Urgent treatment – If systolic/diastolic ≥ 160/110 mm Hg persists > 15 min, give oral nifedipine or intravenous labetalol or hydralazine【17】.
• Seizure prophylaxis – Administer magnesium sulfate (loading 4‑5 g IV over 5 min, maintenance 1‑2 g/h) when severe hypertension is accompanied by proteinuria or neurological symptoms【17】.

6. Timing of Delivery

7. Absolute Indications for Immediate Delivery (any gestational age)

• Refractory severe hypertension despite ≥ 3 antihypertensive classes【12】
• Progressive thrombocytopenia or worsening hepatic/renal laboratory values【15】
• Pulmonary edema or oxygen saturation < 90 %【16】
• Severe neurological manifestations (intractable headache, repeated visual scotomas, seizures)【15】
• Placental abruption or non‑reassuring fetal status【16】

8. Additional Clinical Insights

• Approximately 25 % of gestational hypertension progresses to preeclampsia, often rapidly during labor【16】.

9. Serologic Considerations

• Isolated positive ANA without a defined rheumatologic disorder does not substantially alter preeclampsia risk when antiphospholipid antibodies are negative【12】.
• Nevertheless, screening for antiphospholipid syndrome (anticardiolipin antibodies, lupus anticoagulant) is recommended because of the associated thrombotic risk in pregnancy【12】.

10. Post‑partum Follow‑up

• Monitor blood pressure and clinical status every 4 hours for at least 3 days postpartum, as eclampsia may first present in this period【15】.
• Avoid NSAIDs for post‑partum analgesia unless alternative agents are ineffective, especially in the presence of renal impairment【15】.
• Schedule a comprehensive review at 3 months postpartum to confirm normalization of blood pressure, urine findings and laboratory parameters【15】.

Evidence‑Based Implications of Massive Proteinuria in Severe Preeclampsia

Assessment of Proteinuria

• In women with severe preeclampsia, a spot urine protein‑to‑creatinine ratio is recommended at diagnosis to provide a baseline quantification of protein loss, as documented in the Hypertension study cohort. 18

Clinical Consequences of Massive Proteinuria (>5 g/24 h)

• Massive proteinuria (>5 g per 24 h) is linked to more severe neonatal outcomes, including higher rates of respiratory distress and low birth‑weight infants, according to the Hypertension investigation. 18
• Presence of massive proteinuria is associated with earlier delivery timing, reflecting the need for expedited obstetric management in the studied population. 18
• Women with massive proteinuria have an increased risk of developing nephrotic‑syndrome‑type complications that may necessitate thromboprophylaxis, as reported in the same Hypertension research. 18

Management of Severe Preeclampsia

Delivery Timing and Immediate Indications

• Prompt delivery after maternal stabilization is recommended for all women with severe preeclampsia, with immediate magnesium sulfate administration and aggressive blood‑pressure control targeting systolic 110‑140 mmHg and diastolic 85 mmHg. 19, 20
• Urgent antihypertensive therapy should be initiated within 15–30 minutes when blood pressure reaches ≥160/110 mmHg to prevent maternal cerebral hemorrhage. 20
• Absolute indications for immediate delivery at any gestational age include: refractory severe hypertension despite ≥3 antihypertensive classes, progressive thrombocytopenia, worsening liver or renal function, pulmonary edema or oxygen saturation < 90 %, severe intractable headache/visual changes/eclamptic seizures, or non‑reassuring fetal status. 20
• At ≥37 weeks’ gestation, delivery is advised immediately after stabilization regardless of disease severity or laboratory values. 19, 20
• Between 34–37 weeks:
  
  • Without severe features – expectant management with close monitoring.
  • With severe features – delivery after stabilization. 20
• Below 34 weeks: expectant management in a center with Maternal‑Fetal Medicine expertise and NICU capability, plus antenatal corticosteroids (betamethasone 12 mg IM every 24 h × 2) for fetal lung maturity. 19, 21, 22

Acute Antihypertensive Therapy

• First‑line IV labetalol regimen: 20 mg bolus, 40 mg after 10 min, then 80 mg every 10 min (maximum cumulative dose 220 mg). 19, 20
• Oral immediate‑release nifedipine 10–20 mg, repeat in 30 min if needed. 20
• IV hydralazine 5–10 mg every 20 min as required. 19, 20
• IV nicardipine infusion: start 5 mg/h, increase by 2.5 mg/h every 5–15 min to a maximum of 15 mg/h. 19, 21
• Target blood pressure during acute management: systolic 110‑140 mmHg, diastolic 85 mmHg (absolute minimum < 160/105 mmHg). 19, 20
• Avoid short‑acting sublingual nifedipine, especially when combined with magnesium sulfate, because of risk of uncontrolled hypotension and fetal distress. 21, 22
• Sodium nitroprusside should be reserved as a last‑resort agent due to potential fetal cyanide toxicity when used >4 hours. 19, 21, 22

Chronic Antihypertensive Management (Non‑Severe Hypertension)

• For persistent BP ≥ 140/90 mmHg but < 160/110 mmHg, initiate oral antihypertensives aiming for diastolic ≈ 85 mmHg to reduce progression to severe disease. 20
• Preferred oral agents: methyldopa (first‑line, use with caution in patients at risk for depression), labetalol, and long‑acting nifedipine. Second/third‑line options include hydralazine and prazosin. 19, 20
• Reduce or discontinue therapy if diastolic BP falls below 80 mmHg. 20

Seizure Prophylaxis

• Magnesium sulfate should be administered immediately to all patients with severe preeclampsia, proteinuria + severe hypertension, or neurological symptoms (headache, visual changes). 20
• Loading dose: 4–5 g IV over 5 min (diluted in 250 mL dextrose 5 % or normal saline). Maintenance infusion: 1–2 g/h continuous IV. 20

Laboratory and Fetal Surveillance

• Baseline CBC focusing on hemoglobin and platelet count; platelet count < 100 000/µL signals severe disease. 20
• Comprehensive metabolic panel to assess liver transaminases, creatinine, and uric acid. 20
• Spot urine protein/creatinine ratio ≥ 30 mg/mmol confirms significant proteinuria. 20
• Initial obstetric ultrasound at diagnosis to evaluate fetal biometry, amniotic fluid volume, and umbilical artery Doppler; repeat every 2 weeks if findings are normal, more frequently if growth restriction is present. 20

Mode of Delivery and Labor Management

• Vaginal delivery is preferred for women with hypertensive disorders of pregnancy unless obstetric indications dictate cesarean section. 19, 21, 22
• Antihypertensive therapy should be continued throughout labor and delivery to maintain systolic < 160 mmHg and diastolic < 110 mmHg. 19, 21, 22

Postpartum Management

• Continue antenatal antihypertensives postpartum; replace methyldopa with an alternative agent if it was used during pregnancy. 19, 22
• Choose antihypertensive agents compatible with breastfeeding; methyldopa is often preferred but should be used cautiously in patients at risk for depression. 19, 21, 22
• Schedule follow‑up at 6 weeks postpartum for blood pressure and urine assessment; confirm persistent hypertension with 24‑hour ambulatory monitoring. 19, 21, 22
• Refer women with ongoing hypertension or proteinuria at 6 weeks to a specialist, and evaluate women < 40 years with persistent hypertension for secondary causes. 19, 21, 22

Prevention of Recurrence

• High‑risk or moderate‑risk women should take low‑dose aspirin 100–150 mg daily from gestational week 12 through week 36‑37. 19, 21, 22
• High‑dose calcium supplementation (≥ 1 g/day) may lower the risk of preeclampsia and preterm birth, especially in women with low dietary calcium intake. 19, 21, 22

Clinical Pitfalls

• Do not use serum uric acid levels or the degree of proteinuria as indications for delivery; decisions should be based on maternal‑fetal clinical status. 20
• Routine plasma volume expansion is not recommended, as it does not improve maternal outcomes and may exacerbate complications. 20

Management of High‑Risk Pregnancy with Preeclampsia (Evidence from Hypertension 2018)

Risk Estimation and Counseling

• The probability of developing preeclampsia in a nulliparous woman with a first‑degree family history of severe preeclampsia is approximately 15 %, and the additional risk of gestational hypertension is another 15 %【23】.
• Even without recurrent preeclampsia, there is an elevated risk of fetal growth restriction【23】.

Primary Prevention

• In subsequent pregnancies, low‑dose aspirin (75–162 mg daily) should be started before 16 weeks of gestation (ideally before 12 weeks) and continued until 36–37 weeks【23】.

Maternal Blood‑Pressure Targets and Monitoring

• Desired blood‑pressure range during surveillance is systolic 110–140 mm Hg and diastolic ≤85 mm Hg (or at least <160/105 mm Hg in severe cases)【23】.

Fluid Management

• Total intravenous fluid administration should be limited to 60–80 mL hour⁻¹ to avoid pulmonary edema【23】.
• The goal is euvolemia; aggressive “dry” fluid restriction is discouraged because it may worsen acute kidney injury【23】.

Timing of Delivery

• When gestational age is ≥37 weeks, delivery should be performed promptly after maternal stabilization, regardless of disease severity【23】.
• Severe refractory hypertension despite use of three or more antihypertensive classes constitutes an absolute indication for immediate delivery at any gestational age【23】.

Post‑partum Maternal Surveillance

• Blood pressure and clinical status must be checked every 4–6 hours while the patient is awake for at least the first 3 days after delivery, as eclampsia can first appear in this period【23】.
• Non‑steroidal anti‑inflammatory drugs should be avoided for post‑partum analgesia unless alternative agents are ineffective, especially when renal impairment is present【23】.
• Antihypertensive medications should be tapered slowly after days 3–6 postpartum unless blood pressure falls below 110/70 mm Hg【23】.
• A clinical review should be scheduled within 1 week for any woman who remains on antihypertensive therapy at discharge【23】.

3‑Month Post‑partum Follow‑up

• All women should undergo a comprehensive review at 3 months postpartum, including blood‑pressure measurement, urine analysis, and laboratory testing, to confirm normalization of findings【23】.
• Persistent abnormalities warrant further investigation for secondary hypertension or underlying renal disease【23】.
• Screening for depression, anxiety, and post‑traumatic stress disorder should be incorporated into the 3‑month follow‑up visit【23】.

Long‑Term Cardiovascular Risk

• Women with a history of preeclampsia have a markedly increased lifetime risk of cardiovascular disease, stroke, cardiovascular death, type 2 diabetes, venous thromboembolism, and chronic kidney disease compared with women who had normotensive pregnancies【23】.
• Standard cardiovascular risk calculators may underestimate risk in younger women despite their high long‑term risk【23】.

Recommendations for Future Pregnancies

• Low‑dose aspirin should again be initiated before 16 weeks gestation (ideally before 12 weeks) in any subsequent pregnancy to mitigate recurrence risk【23】.

Acute Management Guidelines for Eclampsia

Severe Hypertension Treatment

• In pregnant patients with eclampsia and severe hypertension (≥160/110 mmHg persisting >15 min), intravenous labetalol is recommended: 20 mg initial bolus, 40 mg after 10 min, then 80 mg every 10 min up to a cumulative maximum of 220 mg. 24
• Intravenous hydralazine may be used as an alternative antihypertensive: 5–10 mg bolus administered every 20 min as needed. 24
• Intravenous nicardipine infusion is another option: start at 5 mg/h, increase by 2.5 mg/h every 5–15 min to a maximum of 15 mg/h. 24

Blood Pressure Targets

• During the acute phase of eclampsia, aim to keep systolic blood pressure < 160 mmHg and diastolic < 110 mmHg. 24
• For maintenance after stabilization, target systolic 110–140 mmHg and diastolic ≈ 85 mmHg. 24

Fluid Management

• Limit total intravenous fluid administration to 60–80 mL per hour to reduce the risk of iatrogenic pulmonary edema. 24
• Routine use of diuretics is discouraged because they further decrease plasma volume, which is already contracted in eclampsia. 24

Delivery Timing and Mode

• Delivery is the definitive therapy for eclampsia and should be performed after maternal stabilization, irrespective of gestational age. 24
• Vaginal delivery is preferred when obstetric conditions allow, reserving cesarean section for specific obstetric indications. 24
• Antihypertensive therapy should be continued throughout labor and delivery to maintain systolic < 160 mmHg and diastolic < 110 mmHg. 24

Postpartum and Follow‑up

• Women with persistent hypertension or proteinuria at 6 weeks postpartum should be referred to a specialist for further evaluation. 24

Critical Pitfalls

• Sublingual nifedipine must be avoided, especially when combined with magnesium sulfate, because of the risk of severe hypotension, myocardial depression, and fetal distress. 24
• Delivery must not be delayed once the mother is hemodynamically stabilized; postponement offers no benefit and may increase maternal risk. 24
• Sodium nitroprusside should not be administered for more than 4 hours due to the potential for fetal cyanide and thiocyanate toxicity. 24